



261 Mountain View Dr  
Colchester, VT 05446  
License #: TLAB0030  
802-767-7256  
info@onwardanalytics.biz

# Certificate of Analysis

**Client Name:** Veracious Cultivation and Genetics  
**License Number:** SCLT0300

**Sample ID:** VT6773  
**Sample Name:** Divine Gary  
**Sample Lot:** MANU0066-243-002  
**Sample Matrix:** Mechanical Extraction Concentrates  
**Date Received:** 1/19/2024  
**Date Reported:** 2/5/2024  
**Date Tested:** 1/23/2024



**Total Terpenes (%) : 5.7269**

## Dominant Terpenes (%)

beta-caryophyllene	2.0712
Limonene	2.0096
alpha-Humulene	0.6391
beta-Pinene	0.3493
alpha-Pinene	0.1769

## Terpenes

Standard terpene analysis utilizing Gas Chromatography – Mass Spectrometry (GC-MS; SOP-069-OA) | Test ID: #19842

Analyte	Result (%)	Result (mg/g)	LOD (mg/g)	LOQ (mg/g)
3-Carene	ND	ND	0.000002	0.002
alpha-Bisabolol	0.1376	1.376	0.000003	0.002
alpha-Humulene	0.6391	6.391	0.000002	0.002
alpha-Pinene	0.1769	1.769	0.000001	0.002
alpha-Terpinene	ND	ND	0.000001	0.002
alpha-Terpinolene	ND	ND	0.000004	0.002
beta-caryophyllene	2.0712	20.712	0.000004	0.002
beta-Pinene	0.3493	3.493	0.000002	0.002
Camphene	< LOQ	< LOQ	0.000001	0.002
Caryophyllene Oxide	< LOQ	< LOQ	0.000011	0.002
Eucalyptol	ND	ND	0.000002	0.002
gamma-Terpinene	ND	ND	0.000002	0.002
Geraniol	ND	ND	0.000008	0.002
Guaiol	0.1028	1.028	0.000007	0.002
Isopulegol	ND	ND	0.000005	0.002
Isopropyl Toluene	ND	ND	0.000003	0.002
Limonene	2.0096	20.096	0.000002	0.002
Linalool	0.0855	0.855	0.000003	0.002
Nerolidol	< LOQ	< LOQ	0.000007	0.002
Myrcene	0.0836	0.836	0.000003	0.002
Ocimene	0.0713	0.713	0.000002	0.002
<b>Total Terpenes</b>	<b>5.7269</b>	<b>57.269</b>		

*Callie Chapman*

Callie Chapman  
Lab Director  
2/5/2024

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.

